Dr Collinson’s career includes executive leadership and board roles with public and private life science companies in the US and Europe, and as a partner with a venture capital firm.
He has served on the boards of companies including Affinium Pharmaceuticals (acquired by Debiopharm), Cabrellis Pharmaceuticals (acquired by Pharmion, now part of Celgene), Conforma Therapeutics (acquired by Biogen), Essentialis (acquired by Capnia, now Soleno Therapeutics), GeneOhm Sciences (acquired by Becton Dickinson), NovaCardia (acquired by Merck & Co), and Vertex Pharmaceuticals.
As a life science partner with Forward Ventures, Dr Collinson has led investments in numerous biopharmaceutical companies. Previously, he was Chairman and CEO of Aurora Biosciences (acquired by Vertex Pharmaceuticals). He held senior management positions at GlaxoWellcome (now GlaxoSmithKline) and Baxter International, and was a consultant with The Boston Consulting Group.
Dr Collinson received an MBA from Harvard Business School (Fulbright Scholar), a DPhil (PhD) in Physical Chemistry from the University of Oxford.